Gossamer Bio (GOSS)

Executive Summary

Gossamer Bio is a clinical-stage biotechnology company focused on developing seralutinib (GB002), an inhaled dry powder inhibitor of PDGFRα/β, CSF1R, and c-KIT, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's lead candidate, seralutinib, targets the underlying vascular remodeling in these diseases through a novel mechanism distinct from current vasodilator therapies. Gossamer has completed a Phase 3 trial (PROSPECT) in PAH with top-line data expected soon, and is actively enrolling a second Phase 3 trial (NCT06274801) in PAH with completion anticipated by end of 2026. Additionally, the company initiated a Phase 3 trial in PH-ILD (NCT07181382) in early 2026, expanding the potential market. With a valuation around $87 million and a focused pipeline, Gossamer represents a high-risk, high-reward opportunity dependent on successful clinical readouts and regulatory outcomes.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 PROSPECT trial top-line data in PAH60% success
• H2 2026Phase 3 PAH trial (NCT06274801) enrollment completion75% success
• H1 2027Phase 3 PH-ILD trial (NCT07181382) initial enrollment update70% success